FMP

FMP

Enter

XFOR - X4 Pharmaceuticals, ...

Financial Summary of X4 Pharmaceuticals, Inc.(XFOR), X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research,

photo-url-https://financialmodelingprep.com/image-stock/XFOR.png

X4 Pharmaceuticals, Inc.

XFOR

NASDAQ

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

1.29 USD

0.06 (4.65%)

About

ceo

Dr. Paula Ragan Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.x4pharma.com

exchange

NASDAQ

Description

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the t...

CIK

0001501697

ISIN

US98420X1037

CUSIP

98420X103

Address

61 North Beacon Street

Phone

857 529 8300

Country

US

Employee

93

IPO Date

Nov 16, 2017

Summary

CIK

0001501697

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

98420X103

ISIN

US98420X1037

Country

US

Price

1.29

Beta

0.46

Volume Avg.

2.44M

Market Cap

216.64M

Shares

-

52-Week

0.572-2.575

DCF

0.23

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.26

P/B

-

Website

https://www.x4pharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest XFOR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep